NCT04111159View on ClinicalTrials.gov

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy

PHASE3CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

December 6, 2019

Primary Completion Date

June 19, 2020

Study Completion Date

July 27, 2020

Conditions
Sedation or Anesthesia
Interventions
DRUG

HSK3486

Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.

DRUG

Propofol

Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.

Trial Locations (1)

Unknown

West China Hospital，Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04111159 - A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy | Biotech Hunter | Biotech Hunter